Weight-loss jab Wegovy sees another prescription boost after ban on copycats - Novo CEO ousted in May, in place until ...

The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark.

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose weight more effectively and stay on track with its flagship medication, Wegovy ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their prescribed obesity medication, according to findings published in Obesity.

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J., June ...